Saudi cohort links semaglutide-dapagliflozin combination to lower heart failure risk

The wire

1. 01A retrospective cohort of 539 adults with type 2 diabetes at King Abdulaziz Hospital, Al-Ahsa, compared dapagliflozin monotherapy with dapagliflozin plus once-weekly injectable semaglutide over six months.
2. 02Combination therapy was associated with a lower relative risk of heart failure (RR 0.43, p=0.04), higher HDL and improved eGFR, despite weaker glycemic control than dapagliflozin alone.
3. 03The myocardial infarction reduction (RR 0.61, p=0.13) was not significant and stroke risk was unchanged; the authors say the retrospective, non-randomized design precludes causal inference.

From the source

Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia

Journal of the ASEAN Federation of Endocrine Societies · 2026 Aug · Alharajin R, AlTaweel M, AlSubaiee M et al.